<DOC>
	<DOCNO>NCT02805244</DOCNO>
	<brief_summary>A mass balance study determine rout rate elimination radioactivity , determine total radioactivity plasma whole blood time compare level JTZ-951 drug-derived entity plasma determine pharmacokinetic ( PK ) parameters JTZ-951 metabolite ( ) .</brief_summary>
	<brief_title>Mass Balance Study JTZ-951 Subjects With End-stage Renal Disease Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Subjects end stage renal disease hemodialysis Postdialysis body weight &gt; 45.0 kg BMI 18.0 40.0 kg/m2 ( inclusive ) Subjects aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.0 × upper limit normal ( ULN ) , total bilirubin &gt; 1.5 × ULN Screening Visit Subjects hepatobiliary disease condition ( biliary cirrhosis ) Subjects positive test result HBsAg ( hepatitis B surface antigen ) , HCV antibody HIV antibody Subjects know history liver failure liver surgery Subjects history current clinically significant chronic acute blood loss</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>JTZ-951</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>14C-JTZ-951</keyword>
	<keyword>Mass balance</keyword>
	<keyword>Time course</keyword>
</DOC>